Year None2023202220212020201920182017 Jan 27, 2023 Legend Biotech Announces Phase 3 CARTITUDE-4 Study of CARVYKTI® (ciltacabtagene autoleucel) Has Met Its Primary Endpoint in the Treatment of Patients with Relapsed and Refractory Multiple Myeloma Jan 09, 2023 Legend Biotech Announces Notification of Delinquency from The Nasdaq Stock Market LLC Jan 03, 2023 Legend Biotech to Participate in the 41st Annual JP Morgan Healthcare Conference Jan 02, 2023 Legend Biotech Announces Acceptance of Its New Drug Application for Ciltacabtagene Autoleucel (Cilta-Cel) in China
Jan 27, 2023 Legend Biotech Announces Phase 3 CARTITUDE-4 Study of CARVYKTI® (ciltacabtagene autoleucel) Has Met Its Primary Endpoint in the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
Jan 02, 2023 Legend Biotech Announces Acceptance of Its New Drug Application for Ciltacabtagene Autoleucel (Cilta-Cel) in China